Study details
Enrolling now
IKS014 Trial for Advanced Cancer
Iksuda Therapeutics Ltd.
NCT IDNCT05872295ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
165
Study length
about 4 years
Ages
18+
Locations
3 sites in CA, MA, TN
What this study is about
This trial is testing IKS014, a new drug, to see if it's safe and effective in people with advanced solid tumors that express HER2. The goal is to determine the best dose of IKS014 for further development.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IKS014
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Objective Response Rate (Part 2)
Secondary: Objective Response Rate (Part 1)
Body systems
Oncology